skip navigation

Skip Nav

AIDSinfo Drug Database

AIDSinfo Drug Database

Drugs by class

FDA-approved

Investigational

Tenofovir Alafenamide  Audio icon

Other Names: GS-7340, TAF, TFV alafenamide, prodrug of tenofovir, tenofovir alafenamide fumarate
Drug Class: Nucleoside Reverse Transcriptase Inhibitors
Molecular Formula: C21 H29 N6 O5 P
Registry Number: 379270-37-8 (CAS)
Chemical Name: isopropyl (2S)-2-[[[(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]propanoate
Chemical Class: Purine Nucleotides
Company: Gilead Sciences, Inc. (The darunavir/cobicistat/emtricitabine/tenofovir alafenamide fixed-dose combination [FDC] is being developed by Janssen R&D Ireland.)
Phase of Development: The following tenofovir alafenamide-containing FDC regimens are in Phase III studies: 1) emtricitabine/tenofovir alafenamide 2) rilpivirine/emtricitabine/tenofovir alafenamide 3) darunavir/cobicistat/emtricitabine/tenofovir alafenamide, and 4) GS-9883/emtricitabine/tenofovir alafenamide. 

Emtricitabine/tenofovir alafenamide and rilpivirine/emtricitabine/tenofovir alafenamide FDC tablets are currently under review by the U.S. Food and Drug Administration (FDA) for marketing approval.

An FDC tablet containing elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (brand name: Genvoya) was approved by FDA in November 2015.
Print

Chemical Image:
Click image to enlarge
tenofovir alafenamide
tenofovir alafenamide
Molecular Weight: 476.4711
(Compound details obtained from ChemIDplus Advanced,1 NIAID Therapeutics Database,Gilead website,3 ClinicalTrials.gov,4,5 and Gilead Sciences, Inc. press releases6,7)

What is an investigational drug?

An investigational drug is one that is under study and is not approved by the U.S. Food and Drug Administration (FDA) for sale in the United States. Medical research studies are conducted to evaluate the safety and effectiveness of an investigational drug. These research studies are also called clinical trials. Once an investigational drug has been proven safe and effective in clinical trials, FDA may approve the drug for sale in the United States.

What is tenofovir alafenamide?

Tenofovir alafenamide is an investigational drug that is being studied for the treatment of HIV infection. It is also being studied for the treatment of chronic hepatitis B virus (HBV) infection.8,9

Tenofovir alafenamide belongs to a class (group) of HIV drugs called nucleoside reverse transcriptase inhibitors (NRTIs).2 NRTIs block an HIV enzyme called reverse transcriptase. (An enzyme is a protein that starts or increases the speed of a chemical reaction.) By blocking reverse transcriptase, NRTIs prevent HIV from multiplying and can reduce the amount of HIV in the body.

Tenofovir alafenamide is a prodrug, which means that it is an inactive drug. Once taken, a prodrug does not work until the body converts it into an active form. In the body, tenofovir alafenamide is converted to tenofovir diphosphate (TFV-DP).10

Studies suggest that tenofovir alafenamide may be more effective against HIV and cause fewer side effects than the FDA-approved NRTI tenofovir disoproxil fumarate (brand name: Viread).11

Tenofovir alafenamide is currently being studied as a component of four different investigational fixed-dose combination (FDC) drugs for the treatment of HIV infection. (Fixed-dose combination drugs include two or more drugs in a single dosage form, such as a capsule or tablet.) Tenofovir alafenamide is being studied in the following combinations: 

  • rilpivirine/emtricitabine/tenofovir alafenamide3
  • emtricitabine/tenofovir alafenamide3
  • darunavir/cobicistat/emtricitabine/tenofovir alafenamide4
  • GS-9883/emtricitabine/tenofovir alafenamide3,5

An FDC tablet containing elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (brand name: Genvoya) was approved by FDA in November 2015.6

How are clinical trials of investigational drugs conducted?

clinical trials are conducted in phases. Each phase has a different purpose and helps researchers answer different questions.12

  • Phase I trials: Researchers test an investigational drug in a small group of people (20–80) for the first time. The purpose is to evaluate its safety and identify side effects.
  • Phase II trials: The investigational drug is administered to a larger group of people (100–300) to determine its effectiveness and to further evaluate its safety.
  • Phase III trials: The investigational drug is administered to large groups of people (1,000–3,000) to confirm its effectiveness, monitor side effects, compare it with standard or equivalent treatments, and collect information that will allow the investigational drug to be used safely.12

In most cases, an investigational drug must be proven effective and must show continued safety in a Phase III clinical trial to be considered for approval by FDA for sale in the United States. Some drugs go through FDA’s accelerated approval process and are approved before a Phase III clinical trial is complete. After a drug is approved by FDA and made available to the public, researchers track its safety in Phase IV trials to seek more information about the drug’s risks, benefits, and optimal use.12

In what phase of testing is tenofovir alafenamide?

Tenofovir alafenamide, as part of four different fixed-dose combination tablets, is currently being studied in Phase III clinical trials.3-5 Applications for marketing approval have been submitted to FDA for emtricitabine/tenofovir alafenamide and rilpivirine/emtricitabine/tenofovir alafenamide FDC tablets.3

What are some studies on tenofovir alafenamide?

Emtricitabine/Tenofovir Alafenamide (F/TAF)
In April 2015, an application for marketing approval for fixed-dose combination (FDC) tablets containing emtricitabine/tenofovir alafenamide was submitted to FDA for use in combination with other antiretroviral (ARV) medicines for the treatment of HIV infection.13

Study Names: GS-US-311-1089; NCT02121795
Phase: III
Location: North America and Europe 
Participants: HIV-infected adults who had taken HIV medicines before entering the study (also called treatment-experienced). Participants had been taking an ARV therapy regimen that contained emtricitabine/tenofovir disoproxil fumarate (brand name: Truvada) plus a third HIV medicine. Participants had a viral load (the amount of HIV in the blood) that was suppressed to less than 50 copies/mL for at least 6 months. 
Purpose: The purpose of this study was to look at the safety and effectiveness of switching from an FDC tablet containing Truvada to an FDC tablet containing emtricitabine/tenofovir alafenamide.
Study Design: This study will last at least 96 weeks. Participants were randomly assigned to one of the following two groups:

  • emtricitabine/tenofovir alafenamide FDC tablet (given as one of two doses) once daily + a third HIV medicine from the participant’s original treatment regimen
  • Truvada once daily + a third HIV medicine from the participant’s original treatment regimen.

In addition to the assigned medicines, participants also received placebo tablets so that everyone ended up taking similar looking tablets and the same number of tablets daily. (A placebo is an inactive drug that is identical in appearance to the active drug being studied.)

Results:

  • The company studying the emtricitabine/tenofovir alafenamide FDC tablets in the GS-US-311-1089 study has reported some Week 48 safety and effectiveness results. Details about these results can be seen in the company’s press release (see Reference 15).14,15


Another Phase III study (GS-US-311-1717) will continue to evaluate emtricitabine/tenofovir alafenamide FDC tablets. This study will look at the safety and effectiveness of switching from abacavir/lamivudine (brand name: Epzicom) to an emtricitabine/tenofovir alafenamide FDC tablet in participants who have viral loads suppressed to less than 50 copies/mL. Participants will also receive a third HIV medicine.16



Rilpivirine/Emtricitabine/Tenofovir Alafenamide (R/F/TAF)
In July 2015, an application for marketing approval for an FDC tablet containing rilpivirine/emtricitabine/tenofovir alafenamide was submitted to FDA for the treatment of HIV infection in individuals who had never taken HIV medicines before (treatment-naive) or in individuals who have suppressed viral loads and want to replace their current ARV treatment regimen.17

Two Phase III “switch” studies (GS-US-366-1216 and GS-US-366-1160) are evaluating a rilpivirine/emtricitabine/tenofovir alafenamide FDC tablet in adults who have viral loads suppressed to less than 50 copies/mL. The studies will look at the safety and effectiveness of switching to a rilpivirine/emtricitabine/tenofovir alafenamide FDC tablet from either emtricitabine/rilpivirine/tenofovir disoproxil fumarate (brand name: Complera) or efavirenz/emtricitabine/tenofovir disoproxil fumarate (brand name: Atripla).18,19



Darunavir/ Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF)
Study Names: GS-US-299-0102; NCT01565850
Phase: II
Location: United States and Puerto Rico 
Participants: HIV-infected, treatment-naive adults
Purpose: The purpose of this study was to look at the safety and effectiveness of darunavir/cobicistat/emtricitabine/tenofovir alafenamide FDC tablet versus cobicistat-boosted darunavir + Truvada over 48 weeks. (Boosting means using an ARV medicine or other drug to increase the effectiveness of another ARV medicine. In this case, cobicistat is used to increase the effectiveness of darunavir.)
Study Design: Participants were randomly assigned to one of the following two groups:

  • darunavir/cobicistat/emtricitabine/tenofovir alafenamide FDC tablet once daily
  • darunavir + cobicistat + Truvada, each given daily 

In addition to the assigned medicines, participants also received placebo tablets so that everyone ended up taking similar looking tablets and the same number of tablets daily.

Results:

  • After 48 weeks, the FDC drug darunavir/cobicistat/emtricitabine/tenofovir alafenamide appeared to be as effective as cobicistat-boosted darunavir plus Truvada in reducing participants’ viral loads.
  • In terms of safety, two participants in each group stopped the study early because of a side effect.
  • The tenofovir alafenamide-containing tablet led to fewer bone- and kidney-related side effects among participants than the treatment containing tenofovir disoproxil fumarate.20-22


Two Phase III studies will continue to evaluate the darunavir/cobicistat/emtricitabine/tenofovir alafenamide FDC tablet in treatment-naive participants and in treatment-experienced participants with viral loads suppressed to less than 50 copies/mL.4,23



GS-9883/Emtricitabine /Tenofovir Alafenamide (GS-9883/F/TAF)
Four Phase III studies will be looking at an FDC tablet containing GS-9883/emtricitabine/tenofovir alafenamide in either treatment-naive participants or in treatment-experienced participants with viral loads suppressed to less than 50 copies/mL. (GS-9883 is an investigational integrase inhibitor that does not require boosting.)3,5,24-26

What side effects might tenofovir alafenamide cause?

In the Phase II study of a darunavir/cobicistat/emtricitabine/tenofovir alafenamide fixed-dose combination tablet discussed under the previous question (GS-US-299-0102), most side effects were mild to moderate in severity. Some side effects that were reported by participants receiving the darunavir/cobicistat/emtricitabine/tenofovir alafenamide tablet included diarrhea, upper respiratory tract infection, fatigue, nausea, and rash.21, 22

Because tenofovir alafenamide is still being studied, information on possible side effects of the drug is not complete. As testing of tenofovir alafenamide continues, additional information on possible side effects will be gathered.

Where can I get more information about clinical trials studying tenofovir alafenamide?

More information about tenofovir alafenamide-related research studies is available from the AIDSinfo database of ClinicalTrials.gov study summaries. Click on the title of any trial in the list to see the ClinicalTrials.gov trial summary and more information about the study.

I am interested in participating in a clinical trial of tenofovir alafenamide. How can I find more information about participating in a clinical trial?

Participating in a clinical trial can provide benefits. For example, a volunteer participant can benefit from new research treatments before they are widely available. Participants also receive regular and careful medical attention from a research team that includes doctors and other health professionals. However, clinical trials may also involve risks of varying degrees, such as unpleasant, serious, or even life-threatening side effects from the treatment being studied.12

Your health care provider can help you decide whether participating in a clinical trial is right for you. For more information, visit NIH Clinical Research Trials and You.

References

 
  1. United States National Library of Medicine. ChemIDplus Advanced. Available at: http://chem.sis.nlm.nih.gov/chemidplus/rn/379270-37-8. Last accessed on December 21, 2015.
  2. National Institute of Allergy and Infectious Diseases (NIAID). NIAID ChemDB, HIV Drugs in Development. Available at: http://chemdb.niaid.nih.gov/DrugDevelopmentHIV.aspx. Last accessed on December 21, 2015.
  3. Gilead website. Pipeline: HIV/AIDS. Available at: http://gilead.com/research/pipeline. Last accessed on December 21, 2015. 
  4. Janssen Sciences Ireland UC. A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Dose Combination Coadministered With Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 Infected Subjects. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on April 27, 2015. NLM Identifier: NCT02431247. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02431247. Last accessed on December 21, 2015.
  5. Gilead Sciences. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on November 10, 2015. NLM Identifier: NCT02607930. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02607930. Last accessed on December 21, 2015.
  6. Gilead: Press Release, dated November 5, 2015. U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection. Available at: http://www.gilead.com/news/press-releases/2015/11/us-food-and-drug-administration-approves-gileads-single-tablet-regimen-genvoya-elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-for-treatment-of-hiv1-infection. Last accessed on December 21, 2015.
  7. Gilead: Press Release, dated December 29, 2014. Gilead Announces Amended Agreements With Janssen to Develop and Commercialize Tenofovir Alafenamide-Based Single Tablet Regimens for HIV Treatment. Available at: http://www.gilead.com/news/press-releases/2014/12/gilead-announces-amended-agreements-with-janssen-to-develop-and-commercialize-tenofovir-alafenamidebased-single-tablet-regimens-for-hiv-treatment. Last accessed on December 21, 2015. 
  8. Gilead Sciences. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on August 20, 2013. NLM Identifier: NCT01940471. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01940471. Last accessed on December 21, 2015.
  9. Gilead Sciences. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on August 20, 2013. NLM Identifier: NCT01940341. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01940341. Last accessed on December 21, 2015.
  10. García-Lerma JG, Aung W, Cong ME, et al. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol. 2011 Jul;85(13):6610-7. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3126530/. Last accessed on December 21, 2015.
  11. Ruane P, DeJesus E, Berger D, et al. GS-7340 25 mg and 40 mg Demonstrate Superior Efficacy to Tenofovir 300 mg in a 10-day Monotherapy Study of HIV-1+ Patients. Paper presented at: 19th Conference on Retroviruses and Opportunistic Infections (CROI); March 5-8, 2012; Seattle, WA. Paper 103. Available at: http://www.retroconference.org/2012b/Abstracts/44081.htm. Last accessed on May 29, 2013.
  12. National Institutes of Health (NIH). NIH Clinical Research Trials and You. Available at: http://www.nih.gov/health-information/nih-clinical-research-trials-you. Last accessed on December 21, 2015.
  13. Gilead: Press Release, dated April 7, 2015. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment. Available at: http://www.gilead.com/news/press-releases/2015/4/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-fixeddose-combination-of-emtricitabinetenofovir-alafenamide-for-hiv-treatment. Last accessed on December 21, 2015. 
  14. Gilead Sciences. A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on April 22, 2014. NLM Identifier: NCT02121795. Available at: http://www.clinicaltrials.gov/ct2/show/NCT02121795. Last accessed on December 21, 2015.
  15. Gilead: Press Release, dated September 2, 2015. Gilead’s Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide (F/TAF) Meets Primary 48-Week Objective in Phase 3 Study. Available at: http://www.gilead.com/news/press-releases/2015/9/gileads-investigational-fixeddose-combination-of-emtricitabinetenofovir-alafenamide-ftaf-meets-primary-48week-objective-in-phase-3-study. Last accessed on December 21, 2015. 
  16. Gilead Sciences. A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed on Regimens Containing ABC/3TC. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on June 9, 2015. NLM Identifier: NCT02469246. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02469246. Last accessed on December 21, 2015. 
  17. Gilead: Press Release, dated July 1, 2015. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF). Available at: http://www.gilead.com/news/press-releases/2015/7/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-single-tablet-regimen-for-hiv-containing-rilpivirine-emtricitabine-and-tenofovir-alafenamide-rftaf. Last accessed on December 21, 2015.  
  18. Gilead Sciences. A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on January 19, 2015. NLM Identifier: NCT02345252. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02345252. Last accessed on December 21, 2015. 
  19. Gilead Sciences. A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/ Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects. In: ClinicalTrials.gov. Registered on January 19, 2015. NLM Identifier: NCT02345226. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02345226. Last accessed on December 21, 2015. 
  20. Gilead Sciences. A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on March 27, 2012. NLM Identifier: NCT01565850. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01565850. Last accessed on December 21, 2015.
  21. Mills A, Ortiz R, Crofoot G Jr, et al. 48 Week Study of the First PI-based Single Tablet-Regimen (STR) Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) vs. Cobicistat (COBI)-boosted Darunavir (DRV) and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Treatment-naïve (TN) Adults. Abstract presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 5-9, 2014; Washington, DC. Abstract H-647c. Available at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=19dd97cd-1a73-4adc-9cdb-36743946ec6b&cKey=d7994d1a-681e-49f4-ba2f-c2a15513b895&mKey=%7b5D6B1802-E453-486B-BCBB-B11D1182D8BB%7d. Last accessed on December 21, 2015. 
  22. Mills A, Ortiz R, Crofoot G Jr, et al. 48 Week Study of the First PI-based Single Tablet-Regimen (STR) Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) vs. Darunavir (DRV) boosted by Cobicistat (COBI) and Emtricitabine/Tenofovir Disoproxil Fumarate (TVD) in HIV-Infected Treatment-Naïve Adults. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 5-9, 2014; Washington, DC. Levin: Conference Reports for National AIDS Treatment Advocacy Project (NATAP); 2014. Available at: http://www.natap.org/2014/ICAAC/ICAAC_07.htm. Last accessed on December 21, 2015.
  23. Janssen R&D Ireland. A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor (bPI) Combined With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in Virologically-suppressed, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on October 17, 2014. NLM Identifier: NCT02269917. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02269917. Last accessed on December 21, 2015. 
  24. Gilead Sciences. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on November 10, 2015. NLM Identifier: NCT02607956. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02607956. Last accessed on December 21, 2015. 
  25. Gilead Sciences. A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on November 10, 2015. NLM Identifier: NCT02603107. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02603107. Last accessed on December 21, 2015.
  26. Gilead Sciences. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on November 10, 2015. NLM Identifier: NCT02603120. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02603120. Last accessed on December 21, 2015.


Last Reviewed: December 21, 2015

Back to Top